Overview

Gender

male

In addition to his Board seat with 3-V, Dr. Young currently serves on the Board of Directors of Novavax, Inc. and on the Board of Trustees of The Phillips Collection Museum of Modern Art in Washington, D.C., and recently graduated first in his class with a Certificate de Cuisine from Le Cordon Bleu Academie d’Art Culinaire de Paris in Paris, France. Previously, Dr. Young was with MedImmune, Inc. from 1988 through 2008 following its sale to AstraZeneca PLC.

During his entire tenure, Dr. Young led MedImmune’s research and development organization and was directly involved in the development of approximately twenty clinical programs and commercialization of Synagis9® , RespiGam®, CytoGam®, Flumist®, and Ethyol®. At the time of his retirement from MedImmune, Dr. Young oversaw R&D functions including approximately 1,500 people and an annual budget in excess of $600 million.

Prior to MedImmune, Dr. Young was a Director in the Department of Molecular Genetics at Smith Kline and French Laboratories. Dr. Young has served on the Boards of Directors of Xencor, Inc., Iomai, Inc. and Arriva Pharmaceuticals, Inc.

He received his Ph.D. in Microbiology and Immunology from Baylor College of Medicine.